Both RG7388 (idasanutlin) [16] and HDM201 [17], orally bioavailable examples of the new generation of MDM2-p53 binding antagonists, efficiently suppress tumor growth in vivo, and clinical trials are currently ongoing to investigate the clinical efficacy of these and other MDM2 inhibitors in a range of cancers. Here, MDM2 is linked to cancer.